Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Subscribe To Our Newsletter & Stay Updated
